Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

Dean Li will take over a Merck Research Laboratories that has been transformed by Roger Perlmutter over the past seven years, guiding a pharma that had been struggling with a patent cliff to the company that churns out approval after approval for blockbuster cancer drug Keytruda.  

Li joined Merck in 2017 as VP and head of translational medicine at Merck Research Laboratories following more than two decades at the University of Utah, where he departed as professor of medicine and cardiology, CSO, associate VP and vice dean of the University of Utah Health System. ...